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than solid cancer (odds ratios (ORs) 1.29–3.17) and being married rather than divorced (ORs 1.17–2.54) were most consistently
associated with home death across countries.
Conclusions: A large country variation in the place of death can partly be explained by countries’ healthcare resources. Country-
specific choices regarding the organisation of end-of-life cancer care likely explain an additional part. These findings indicate the
further challenge to evaluate how different specific policies can influence place of death patterns.
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Although life extension and outright cures are possible now for
many types of cancers, it remains one of the leading causes of death
worldwide. Advanced cancer patients form a large group among
people who could benefit from a care approach aimed at comfort
and quality of life (Smith et al, 2012). One important aspect of this
approach is respect for patient choices in terms of the places where
they receive ongoing care, spend the last days of their lives and
ultimately die (Davies and Higginson, 2004). Evidence across many
studies suggests that, for the majority of people with cancer and
their caregivers, home is the preferred place of death (Gomes et al,
2013). Previous research indicates that dying in one’s home
environment is better aligned with patient’s well-being as it
benefits control, autonomy, dignity and continuity of care and
involves lower healthcare costs and less risk of iatrogenic events
and overly aggressive treatments (Marie Curie Cancer Care, 2012;
Higginson et al, 2013; Boockvar et al, 2014).
At the population level, place of death is a valid indicator of
where care is provided in the final hours or days of life (Earle,
2003). Cancer is a leading cause of death worldwide, and so
knowing where people with cancer die and understanding the
determinants of dying in a particular place are important public
health issues, relevant not only to a commitment to patient
preferences but also to efforts to avoid unnecessary hospitalisations
(House of Commons Health Committee, 2004; Federale
Evaluatiecel Palliatieve Zorg, 2008; Pennec et al, 2013). Several
countries have developed policies and programmes to strengthen
palliative and end-of-life care at home and to facilitate dying in the
place of choice (Department of Health, 2008; Wright et al, 2008;
Van Beek et al, 2013).
Population-level monitoring of place of death trends provides
descriptive information that, if complemented with more in-depth
understanding, can help inform public health policy regarding the
allocation of end-of-life care resources and to support improve-
ment strategies. Adding a cross-national comparison provides an
opportunity to examine differences in place of death between
countries with different levels of palliative care integration and
different policies related to, amongst others, cancer care, long-term
care and end-of-life care. This can help generate hypotheses
regarding the influence of different factors related to policy and
healthcare organisation and strategies for influencing where people
die (Hantrais, 2008). Although previous studies have looked at
cross-national differences in place of death in Europe (Cohen et al,
2010; Houttekier et al, 2010), no studies using individual data have
made comparisons across continents.
The aim of this study was to describe the place of death of
cancer patients and associated characteristics in 14 countries across
4 continents. We investigated where people with cancer die in 14
countries across 4 continents and how this differs from where
people with a non-cancer condition die, to what extent differences
in patient characteristics and healthcare supply explain variations
between countries in place of death and to what extent the place of
death of cancer patients is associated with patient characteristics
and healthcare supply in each of the countries studied.
MATERIALS AND METHODS
Study design. This study is part of the International Place of
Death project, which collected complete death certificate data for a
period of 1 year in 14 countries (Table 1). We obtained full country
data except for Spain, where the data are from the Andalusia
province, and Canada where the data do not include the Quebec
province. An exploration of all candidate partners showed that, at
the time of the data collection (2011–2013), 2008 was the most
recent year for which data were available in most targeted
countries. In the USA, 2007 was the most recent available year
and in Andalusia (Spain), place of death was not recorded before
2010. We also obtained a number of clinical, socio-demographic
and residential characteristics of the deceased, factors already
identified as being associated with the place of death in people with
cancer.(Gomes and Higginson, 2006) The project lead coordinated
all data requests to ensure similar variables and data and pooled all
data into one common database. Ethics approval was not required
as we studied anonymised death certificate data.
Data. All included countries have similar death certification:
generally the attending physician certifies the sex of the deceased,
the cause or causes of death and the day and place of death.
The authorities in each country check these certificates for
inconsistencies and code death causes according to the WHO’s
International Classification of Diseases 10th Revision (ICD-10).
The death certificates of some countries contain socio-demo-
graphic information, while in other countries it can be gained
through links with other databases (e.g., census data). A minimum
number of socio-demographic variables were thus obtained.
Available healthcare resource statistics per capita were also
obtained for the healthcare regions within the countries studied
and linked to the region of residence of each deceased cancer
patient (Supplementary Table S1, Supplementary Material).
Measures. The place of death was derived from the death
certificate and comprised at minimum the categories home,
hospital and nursing home/care home in all countries except
Hungary where only hospital and other location were distinguished
and Mexico where nursing home/care home is not a recorded
category because there are no such facilities. We henceforth refer to
nursing home/care as ‘long-term care facility’.
As independent variables we included individual socio-
demographic (age, sex, marital status) and clinical characteristics
(dying from cancer, including respiratory, gastrointestinal,
genitourinary, haematologic and other cancers, or from a non-
cancer condition excluding deaths from external causes such as
accident and homicide), degree of urbanisation of the region of
residence and healthcare supply measures that were identified as
relevant in the literature on place of death of people with cancer
(Gomes and Higginson, 2006). The codes of the municipality/local
authority of residence were matched with available data on
urbanisation levels and healthcare supply. The healthcare supply
data included the number of hospital beds per 10 000 inhabitants, the
number of family physicians or general practitioners per 10 000
inhabitants and the number of long-term care beds per 1000
inhabitants aged 65 years or over, each per health region of residence
of the deceased. In some countries, the individual’s region of
residence was not identified. For those countries we used nationally
aggregated measures of healthcare supply.
Statistical analysis. In the 14 countries all deaths with cancer as
an underlying or primary cause of death (ICD-10 codes C00-C97)
were selected. The cause of death was recorded as solid vs
haematological cancer. Descriptive statistics were used to describe
the place of death. Relative risks (unadjusted risk ratios) were
calculated to compare the chances of dying in a certain setting for
those with cancer and all those without cancer (excluding deaths
from external causes).
To evaluate to what extent the country differences in place of
death could be accounted for by clinical and socio-demographic
characteristics or healthcare supply, a hierarchical binary logistic
regression using all cancer deaths with place of death (home vs
elsewhere) as the dependent variable and country as an
independent variable (Model 1) was expanded by entering cancer
type (18 types of cancer), age, sex and marital status (Model 2), and
then density of hospital beds, long-term beds and general
practitioners (Model 3) into the model. This method was chosen
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as it allows evaluating how certain groups of variables explain part
of the variation between countries.
To evaluate to what extent the place of death of cancer patients
was associated with patient characteristics and healthcare supply in
each of the countries studied a multivariable binary logistic
regression analysis (home vs elsewhere) for all cancer patients was
conducted for each country with various independent candidate
variables (see Supplementary Material for more information).
All models were checked for multicollinearity by looking at
tolerance values and variance inflation factors. Analyses were done
in IBM SPSS Statistics 22.
RESULTS
Population and healthcare availability per country. In the
countries studied, between 13% (Mexico) and 30% (Netherlands)
of all deaths had cancer listed as the underlying cause (Table 1).
The percentage of women among those who died of cancer was
slightly less than 50% in all countries except Mexico; in all
countries around half died between the age of 60 and 79; around
one-third died at the age of 80 or over except in Mexico (19%) and
South Korea (17%). Mexico was the only country where more than
one-third (35%) died between the age of 0 and 59. Between 51%
(US) and 65% (South Korea) of those who died of cancer had been
married (Supplementary Table S2, Supplementary Material).
A relatively high number of beds (more than 70 per 10 000
population) existed in hospitals in Korea, Hungary, France, Czech
Republic and Belgium, while a relatively high number of long-term
care beds (more than 70 per 1000 population aged 65 or over)
existed in the Netherlands, New Zealand and Belgium
(Supplementary Table S3, Supplementary Material).
Place of death per country. Between 12% (Korea) and 56%
(Mexico) of people who died of cancer died at home. The largest
proportion of home deaths was in Mexico, followed by the
Netherlands (46%), Italy (45%) and USA (39%). Deaths in hospital
ranged from 26% in the Netherlands and New Zealand to 87% in
Korea (Table 2).
As compared with persons dying from natural non-cancer
conditions, those dying from cancer had a higher probability of
dying at home in most countries except France, Spain, the Czech
Republic and Korea (Table 2); but they also had a higher
probability of dying in hospital in France, Spain, Belgium Czech
Republic, Hungary, Canada and South Korea. In all countries,
those who died of cancer were less likely to die in a long-term care
facility than those who died of non-malignant causes. People with
cancer also had a higher probability of dying in a palliative care
institution (in countries where such a place was registered) than
did those who died from non-cancer conditions, although this
difference was much smaller in the United States (unadjusted
relative risk (RR)¼ 2.52) and the Netherlands (RR¼ 4.06) than in
England (RR¼ 28.67), Wales (RR¼ 32.00) and New Zealand
(RR¼ 14.54).
Multivariable analysis aimed at explaining country variation in
home deaths. The country differences in the likelihood of dying at
home vs another location (Model 1) remained largely unchanged
when we controlled for differences between countries in cause of
death, age and sex (Model 2; Figure 1; odds ratios (ORs) and 95%
confidence intervals (CI) at each step of analysis in Supplementary
Table S4, Supplementary Material). However, when the density of
Table 1. Deaths from cancer and socio-demographic characteristics in 2008a in 14 countries
Type of cancer (% of all deaths) Age
(% of all cancer
deaths
Country Abbreviations
Total
number of
deaths
Deaths from
cancer
N (% of all
deaths) Respiratory
Gastro-
intestinal Genitourinary
Haemato-
logical other
Sex
(% of all
cancer deaths
% women 0–59 60–79
80
and
above
Continental Western Europe
France FR 541135 153576 (28.4) 5.8 8.5 4.6 2.4 7.1 41.2 19.3 47.4 33.4
Italy IT 578 192 164297 (28.4) 6.1 9.8 4.1 2.4 6.0 43.3 13.1 51.7 35.3
Spain (Andalusia)a ES 57380 15194 (26.5) 6.1 8.6 4.8 1.9 5.1 36.9 18.4 52.6 29.0
Belgium BE 102924 26749 (26.0) 6.6 7.1 4.1 2.1 6.1 43.4 17.0 50.7 32.4
Netherlands NL 135136 40750 (30.2) 7.5 9.0 5.0 2.2 6.4 46.3 18.0 52.6 29.4
Central/Eastern Europe
Czech Republic CZ 101804 26996 (26.5) 5.6 8.8 4.7 1.7 5.8 44.4 19.9 57.2 22.9
Hungary HU 130027 32111 (24.7) 6.9 8.0 3.4 1.4 5.0 44.3 27.2 53.5 19.3
UK
England ENG 475763 128802 (27.1) 6.1 7.6 4.7 2.1 6.6 47.7 13.7 50.9 35.4
Wales WAL 32066 8681 (27.1) 6.5 7.8 4.5 2.0 6.3 47.0 13.1 52.2 34.6
Oceania
New Zealand NZ 29312 8454 (28.8) 5.8 8.8 4.9 2.6 6.8 46.8 17.9 51.1 31.0
North America
Canadab CA 182134 51622 (28.3) 7.3 7.7 4.4 2.6 6.4 47.3 17.9 49.9 32.2
United Statesa US 2428342 563569 (23.2) 6.7 5.6 3.5 2.3 5.1 48.0 20.6 49.6 29.8
Latin America
Mexico MX 528093 65812 (12.5) 1.4 4.0 2.8 1.4 2.9 51.0 35.5 45.8 18.8
East Asia
South Korea KR 247757 69297 (28.0) 6.3 15.3 2.2 1.4 2.8 36.4 26.2 56.7 17.0
Total 5 570065 1 355910 (24.3)
Percentages may not add up to total due to rounding.
aReference year is 2007 in USA and 2010 in Spain (Andalusia).
bThe data for Canada exclude the province of Quebec.
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hospital and long-term care beds and the density of general
practitioners per health region were added to the model
(i.e., assuming a similar density of available healthcare resources;
Model 3), a larger part of the differences was explained as the
difference in the chances of dying at home between France
(reference category) and several other countries was reduced.
Controlling for all covariates, the chances of dying at home still
remained higher in Italy, Belgium, the Netherlands, New Zealand,
the United States and Mexico as compared with France.
Factors associated with death at home within each country.
When the effects of socio-demographic and healthcare supply
factors were adjusted for, a death from a solid tumour was in all
countries more likely to occur at home than a death from a
haematologic cancer, although the difference was larger in some
countries than others (e.g., OR¼ 3.17 (95% CI 2.99–3.35) in
Mexico, OR¼ 1.29 (95% CI 1.14–1.46) in South Korea; Table 3).
The chances of dying at home gradually increased with age in
France, Italy, Spain, Mexico and Korea but decreased with age in
all other countries (except Czech Republic where no clear age
pattern emerged). In all countries married people were more likely
to die at home compared with the divorced, unmarried and
widowed. In all European countries with educational attainment
data available (Italy, Spain, Belgium and Czech Republic), those
with higher educational attainment had better chances of dying at
home than those with lower educational attainment. In the USA,
no clear differences by educational attainment were found, and in
Mexico and Korea an opposite pattern was found; those with
higher educational attainment had lower chances of dying at home.
A lower degree of urbanisation was related to higher chances of a
cancer death at home, except in Canada and France where the
opposite was true. The chances of dying at home decreased with an
increasing density of hospital beds in France, Italy, Belgium, USA,
Canada and Mexico, with the largest effect found in Italy. No clear
association was found across countries between the chances of
dying at home and the density of long-term care beds or the
density of general practitioners per region of residence. The
regression models explained a small proportion of the variation in
dying at home vs elsewhere (R2 range from 0.02 in Czech Republic
to 0.21 in Italy).
DISCUSSION
Our study found a strikingly large variation across 14 countries in
the place of death of people with cancer, especially in the extent to
which home (percentages ranging from 12 to 57%) or hospital
(percentages ranging from 26 to 87%) was the place of death. These
large country differences were explained only to a limited extent by
demographic differences (age, sex), cancer site and healthcare
supply (rate of hospital beds, long-term care beds and general
practitioners per health region), which indicates that a large part of
the variation between countries is attributable to other factors.
There were also notable differences between countries in the
strength and direction of associations between various factors
(e.g., age) and the chances of dying at home, while some factors
were consistently associated with home death in the same direction
(e.g., solid vs nonsolid tumour and marital status).
To our knowledge, this is the largest cross-national study on the
place of death of people who died from cancer, having examined
over 1.3 million deaths in 14 countries on 4 continents. Death
certificate data have the major advantage that they provide
population-level data that do not suffer from potential bias
inherent to samples, and ensure good statistical power to evaluate a
larger number of associated factors. Similarities in death certifica-
tion and cause of death coding make the pooling of the individual
country data for cross-national analysis both feasible and reliable.
They also entail a number of limitations. Inaccuracies in cause of
death recording through death certificates have been reported
(O’Sullivan, 2011). With regard to cancer, this mainly concerns
site-specific accuracy rather than causes other than cancer being
recorded (Lund et al, 2010). Our use of aggregated cause of death
categories (solid vs haematological cancer) may have mitigated this
problem. Coding of place of death is not uniform across countries
(i.e., categories like hospice/palliative care institution in most
countries are missing and in Hungary only hospital vs outside
hospital is coded), and this reaffirms previous calls for more
standardisation and completeness in place of death coding on
death certificates (Cohen et al, 2007; Pivodic et al, 2013). Death
certificate data do not provide all important factors known to
influence place of death (Gomes and Higginson, 2006). Informa-
tion needed to estimate the clinical predictability of dying in a
certain care setting, such as detailed clinical events and symptoms,
is not provided and death certificates do not shed light on the
reasons for hospitalisation at the very end of life (Cohen et al,
2007). Differences between countries in these factors may have
been able to explain an additional part of the country differences in
place of death. Another limitation is that the same set of variables
potentially associated with place of death is not available in all
countries (e.g., hospital bed availability per healthcare region).
However, an evaluation of the influence of the omission of factors
in some countries indicated that these only marginally affected the
Table 2. The place of death of cancer and non-cancer deaths in 14 countries during 2008
Place of death FR IT ES BE NL CZ HU ENG WAL NZ CA US MX KR
Cancer Home 19.1 45.3 31.6 28.9 46.3 18.2 /a 26.1 26.2 28.5 16.1 39.0 57.3 11.8
Hospital 72.8 47.3 64.9 59.3 25.8 64.7 67.7 44.4 56.6 26.2 67.6 33.7 39.9 87.2
Nursing home 5.5 3.9 3.3 11.2 19.3 16.6 /a 10.9 6.0 24.0 11.4 16.3 /a 0.8
PC institutions /a /a /a /a 7.3 /a /a 17.2 9.6 18.9 /a 5.3 /a /a
Others 2.7 3.5 0.2 0.6 1.4 0.5 32.3 1.4 1.6 2.5 5.0 5.8 2.7 0.2
Non-cancer patientsb Home 29.4 41.1 34.9 21.0 18.8 22.5 /a 17.3 17.1 18.8 13.3 20.8 45.9 27.9
Hospital 52.7 46.9 54.8 48.4 33.5 56.1 61.3 59.8 65.4 38.1 59.4 47.6 50.4 68.5
Nursing home 13.9 7.6 9.6 29.1 42.0 18.9 /a 20.7 15.2 36.4 22.7 25.6 /a 2.2
PC institutions /a /a /a /a 1.8 /a /a 0.6 0.3 1.3 /a 2.1 /a /a
Others 4.1 4.4 0.7 1.5 3.9 2.5 38.7 1.7 2.1 5.4 4.5 3.9 3.7 1.3
Unadjusted relative risks: Home 0.65 1.10 0.91 1.38 2.46 0.81 /a 1.51 1.53 1.52 1.21 1.88 1.25 0.42
(Cancer vs non-cancer) Hospital 1.38 1.01 1.18 1.23 0.77 1.15 1.10 0.74 0.87 0.69 1.14 0.71 0.79 1.27
Nursing home 0.40 0.51 0.34 0.38 0.46 0.88 /a 0.53 0.39 0.66 0.50 0.64 /a 0.36
PC institutions /a /a /a /a 4.06 /a /a 28.67 32.00 14.54 /a 2.52 /a /a
Others 0.66 0.80 0.29 0.40 0.36 0.20 0.83 0.82 0.76 0.46 1.11 1.49 0.73 0.15
Abbreviations: BE¼Belgium; CA¼Canada; CZ¼Czech Republic; ENG¼England; ES¼ Spain; FR¼ France; HU¼Hungary; IT¼ Italy; KR¼ South Korea; MX¼Mexico; NL¼Netherland;
NZ¼New Zealand; PC¼palliative care; US¼United States; WAL¼Wales. Missing data for place of death: Korea (0.1%), USA (0.2%), Czech Republic (0.8%), Italy (4.8%) and Mexico (4.9%).
aLocation not recorded on death certificates.
bExcludes all deaths from external causes.
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ORs of the other variables in the multivariable analysis. We
therefore believe that the effects of different factors within a
country can be compared between countries. Conceptual equiva-
lence is a common issue in cross-national comparative research.
In our study, acute hospitals and long-term care settings can have
different characteristics in different countries, and this should be
kept in mind when interpreting the country differences in place of
death, controlled for availability of hospital beds, long-term care
beds and general practitioners.
Although caution not to overinterpret the found country
differences is necessary and multiple complex reasons can underlie
these differences, they do present real differences in terms of where
similar patients spend their final hours. The statistical patterns of
place of death across the different countries can be interpreted as
empirical indications of the way in which each country manages
end-of-life care. The findings of this study provide two important
types of information for addressing some of the public health
challenges related to end-of-life cancer care. Firstly, the findings
inform decisions regarding the allocation of end-of-life cancer care
resources, support and improvement strategies. In some countries,
notably France, Spain, Belgium, Czech Republic, Hungary, Canada
and Korea (countries with 60% or more of cancer deaths occurring
in hospital), the hospital appears to have an important role in
terminal cancer care. In other countries, notably Italy, the
Netherlands, the USA and Mexico, the home setting has a more
prominent role. Although high quality terminal care needs to be
promoted and safeguarded in all care settings, the findings imply
that some countries should primarily focus on evaluating and, if
needed, improving resources for terminal cancer care in hospitals,
while the focus in other countries should be the home setting.
In countries where a high percentage of people with cancer die at
home, such as Mexico, where this is likely to be due to issues of
accessing (institutional) healthcare and where dying at home
may imply dying without professional support (Ca´rdenas-
Turanzas et al, 2011), guaranteeing a ‘good death’ at home is a
major public health challenge. Our findings also illustrate that,
although long-term care facilities are often overlooked as places
for cancer care (Fennell, 2009), they are important places of
death for people with cancer in some countries (e.g., Netherlands
and New Zealand). It is important therefore to ensure that
terminal and end-of-life care in those settings meets the specific
needs of those with cancer.
Secondly, our findings highlight factors that could potentially
influence place of death patterns. Country variation in place of
death can to a certain degree be attributed to the availability of
hospital and long-term care beds or general practitioners.
However, a large part of the country variation in place of death
remained unexplained. A review of country-level data for
contextual explanation of the differences did not show any clear
association between country patterns of place of death and their
health expenditure or social expenditure as a percentage of the
GDP, nor the availability of palliative care resources
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Figure 1. Country differences (ORs) in home death (vs other), accounting for socio-demographic factors, cause of death and healthcare supply.
Hierarchical binary logistic regression analyses with home vs all other places of death as dependent variable. France is the reference category in
the independent variable country. Independent variables: Model 1: country (reference category: France); Model 2: additionally sex, age, cancer
site (17 categories: head and neck; stomach; colon, rectum and anus; pancreas; other gastrointestinal; trachea, bronchus and lung; other
respiratory; breast; cervix uteri, corpus uteri and ovary; prostate; urinary tract; other genitourinary; central nervous system; Non-Hodgkin’s
lymphoma; leukaemia; and other haematologic malignancies); Model 3: additionally number of hospital beds per 1000 inhabitants, long-term care
beds per 1000 inhabitants, and general practitioners per 10 000 inhabitants in the region of residence. Comparing the three models allows
evaluating whether certain variables explain part of the variation between countries. ORs getting closer to each other and closer to 1 when
independent variables are added to the model means that part of the variation in place of death between countries is explained by these
independent variables. For many countries this is particularly the case in Model 3, which indicates that the variables entered in Model 3 explain
part of the variation (more than the ones entered in Model 2). Model 3 provides the ORs for home death of the different countries as compared
with France in case the density of available health resources was the same as in France. In some countries (Spain, England and Wales) the larger
ORs compared with France became smaller than 1, which suggests that if these countries had the same healthcare supply as in France the home
death rate could be expected to be lower than in France. However, a large part of the variation between countries remained unexplained and thus
needs to be attributed to other factors.
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(Supplementary Table S5, Supplementary Material); (Pastrana
et al, 2012; Centeno et al, 2013; Cleary et al, 2013a, b). This
suggests that other more complex health or social policy
differences, particularly those related to end-of-life cancer care,
have a role that cannot easily be captured in a density or
availability measure. Past policies could explain why in some
countries (France, Spain and Korea), cancer patients were less
likely than non-cancer patients to die at home, although cancer
patients are often considered as having a more predictable course
of disease that increases the chance of a home death (Murtagh et al,
2004). In countries such as France, Spain, Canada and Korea, end-
of-life cancer care is more often provided in hospital (in palliative
care units or other wards) than at home. In France, it appears that
there is little support for palliative home care and this carries the
risk of aggressive care in the final stages (Observatoire National de
la Fin de Vie, 2013). In the Czech Republic, palliative home care is
not recognised in the national health insurance law and so
provision is low (Slama, 2009). Many patients are thus treated in
hospitals, often without palliative care. On the other hand,
countries such as the Netherlands (and to a lesser extent the
USA) seem to have explicitly chosen to focus on the provision of
palliative care at home, which would limit hospital use. England’s
End-of-life Strategy has a strong focus on primary care and
previous research has suggested that it may be the reason for the
increased home deaths there (Gao et al, 2013).
It needs to be acknowledged that the place of death patterns we
found in people with cancer, as well as the choices in national
healthcare organisation that may underlie them, are also the result
of historical contingencies and cultural values or circumstances
surrounding families and death and dying in the community
(Brown and Colton, 2001).
CONCLUSIONS
Where cancer patients die appears to be determined by factors
beyond medical necessity or patient characteristics. Countries’
healthcare resources, notably availability of hospital beds and
long-term care beds, explained part of the country variation
in place of death. Healthcare policies specific to end-of-life care
likely explain an additional part. This may suggest that choices
regarding organising end-of-life cancer care within a society can
influence where people receive end-of-life care and die. Further
cross-national research applying a more case-oriented qualitative
in-depth comparison between a number of relevant comparator
countries is needed to understand the reasons behind the
differences in place of death.
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